Aug 5, 2026 04:50PM
Jul 14, 2026 11:39AM
Jul 13, 2026 10:38PM
Jul 13, 2026 10:37PM
Jul 13, 2026 12:02AM
Jun 30, 2026 02:44AM
Jun 16, 2026 08:00AM BioAge Labs begins Phase 2 trial of NLRP3 inhibitor BGE-102
Jun 16, 2026 08:00AM
May 25, 2026 03:33AM
May 15, 2026 02:55AM
May 8, 2026 09:00AM
May 8, 2026 02:48AM
May 8, 2026 02:48AM
May 8, 2026 02:47AM Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
Apr 21, 2026 07:01AM
Apr 21, 2026 07:00AM
Mar 24, 2026 09:00AM
Mar 23, 2026 03:50AM
Feb 6, 2026 06:17AM
Jan 21, 2026 10:30PM
Jan 21, 2026 10:30PM BioAge Announces Pricing of Upsized $115.0 Million Public Offering
Jan 20, 2026 04:01PM
Jan 20, 2026 04:01PM
Jan 20, 2026 09:01AM
Jan 20, 2026 09:00AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Dec 8, 2025 06:42PM Leqembi included in China's commercial insurance innovative drug list
Dec 4, 2025 09:01AM
Dec 4, 2025 09:00AM
Dec 4, 2025 02:13AM
Nov 18, 2025 07:02PM
Nov 13, 2025 06:50PM
Nov 6, 2025 04:45PM
Oct 26, 2025 10:56PM Health Canada Grants Authorization for Leqembi® (lecanemab)
Sep 2, 2025 11:01PM
Aug 25, 2025 03:26AM
Aug 15, 2025 09:00AM
Aug 15, 2025 09:00AM
Aug 6, 2025 04:30PM
Jul 30, 2025 10:54PM
Jun 21, 2025 06:00PM BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Jun 17, 2025 09:08AM
Jun 17, 2025 09:00AM
Jun 3, 2025 09:00AM
May 29, 2025 09:00AM
May 29, 2025 09:00AM
May 15, 2025 04:56AM
May 8, 2025 07:49AM Exidavnemab phase 2a study expanded to include MSA patients
May 6, 2025 04:30PM

328,141 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All